Cassava Sciences Says Results of Study on Investigational Alzheimer's Treatment to be Reassessed
6/3/20, 12:01 PM
Cassava said it also plans to analyze lymphocyte and plasma samples from all study participants and effects of PTI-125 on cognition over the coming months, with results expected in the second half of the year.
GOING UP ^^^^^^^^
Cassava Sciences Shares Jump on Plans for PTI-125 Study Data
6/3/20, 10:08 AM
Cassava Sciences Inc.'s shares rallied Wednesday after the biotechnology company said it has mapped a strategy to better understand the overall outcome of a Phase 2b trial of PTI-125, its lead therapeutic product candidate for the treatment of Alzheimer's disease.
BOOM BOOM BABY
SHORTS ARE GETTING FUKED !
Adding 1k blocks